Inclusion Criteria:  Are capable of giving informed consent and complying with study procedures; Are males between the ages of 18 and 60 years, inclusive; Have a clinical diagnosis of AGA; Considered healthy by the PI, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs; Have normal renal and hepatic function as determined by the screening laboratory results; Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening; Body mass index (BMI) of 19.0 to 35.0 kg/m2 inclusive and body weight not less than 50 kg; Willing and able to adhere to study restrictions and to be confined at the clinical research center.  Exclusion Criteria:  Clinically significant history of gastrointestinal (GI), cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity; Any visible skin disease, damage or condition at the application site which, in the opinion of the investigator, could compromise subject safety and/or interfere with the evaluation of the test site reaction; Subject has any dermatological disorders of the scalp; Subject has a history of hair transplants, hair weaves; Subject has hypersensitivity to previously prescribed minoxidil or finasteride; Known or suspected malignancy; Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag), or hepatitis C (HCV) antibody; A hospital admission or major surgery within 30 days prior to screening; Participation in any other investigational drug trial within 30 days prior to screening; A history of prescription drug abuse, or illicit drug use within 6 months prior to screening; A history of alcohol abuse according to medical history within 6 months prior to screening; A positive screen for alcohol or drugs of abuse; Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening; Use of prescription or over the counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at < 3g/day was permitted until 24 hours prior to dosing); An unwillingness of male participants to use appropriate contraceptive measures if engaging in sexual intercourse with a female partner of childbearing potential. Appropriate measures include use of a condom and spermicide and, for female partners, use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, progesterone subdermal implants, or a tubal ligation.